Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752519 | 0.88 | GRM1 (0.59) | GRM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL12529489 | 0.85 | GRM1 (0.53) | GRM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL6082830 | 0.79 | TSHR (0.52) | MEN1KMT2AALDH1A1TSHRCLEC4M | |
| SCHEMBL10090785 | 0.78 | GRM1 (0.53) | GRM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL8198680 | 0.78 | GRM1 (0.53) | GRM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL1493615 | 0.78 | ALDH1A1 (0.49) | GRM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL10937858 | 0.77 | TSHR (0.51) | GRM1KMT2AALDH1A1TSHRCLEC4M | |
| SCHEMBL4488854 | 0.77 | JAK2 (0.54) | MEN1KMT2AALDH1A1TSHRCLEC4M | |
| SCHEMBL7116182 | 0.77 | CCNC (0.47) | MEN1KMT2AALDH1A1GABRA1GABRB2 | |
| SCHEMBL1156930 | 0.76 | GABRA1 (0.50) | GRM1MEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642257-B2 | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7419978-B2 | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080167304-A1 | PHENYL-ANILINE SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-10 | — | — | US | disclosed |
| US-20050143398-A1 | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
| WO-2005042537-A1 | PHENYL-ANILINE SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167304-A1 | PHENYL-ANILINE SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | GRM1 1786/4885MEN1 2648/4885KMT2A 391/4885 |
| US-20050143398-A1 | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | MAP4K2, MAP3K19, MAP3K1 | GRM1 1786/4885MEN1 2648/4885KMT2A 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.